Testing a new biologic for hard-to-treat rheumatoid arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't improved after trying multiple treatments. It aims to see if the drug can reduce joint pain and swelling when other medications have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with rheumatoid arthritis (RA) by a doctor.
- You've tried at least two standard arthritis drugs plus a biologic or targeted treatment, but they did not control your symptoms.
- If you take steroid medication, your dose must be stable (10 mg/day or less) for at least 4 weeks before starting.
- You do not have another autoimmune disease, active infections, cancer, or severe heart, liver, or kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called TLL-018 for people with moderate to severe rheumatoid arthritis who have not improved enough with standard disease-modifying drugs. It aims to see if the drug can reduce joint pain and swelling.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This trial tests an investigational drug for people with moderate-to-severe rheumatoid arthritis who haven't responded well to previous treatments. It aims to see if the drug can reduce joint pain and swelling.
This trial tests a new drug called telitacicept for people with lung scarring caused by connective tissue diseases. It aims to see if the drug can improve lung function and slow down the disease progression.
This clinical trial tests a new drug called telitacicept for people who have both Sjögren's syndrome and interstitial lung disease. The drug aims to reduce the immune system's attack on your body and may help improve lung symptoms.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.